Related Experiment Video
Updated: Jun 21, 2026

08:14
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
15.5K
Genomic classifier: biomarker for progression in interstitial lung disease
Raymond Parrish1, Fayez Kheir1
1Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, USA.
ERJ Open Research
|May 8, 2025
Summary
A novel genomic classifier may predict disease progression in patients with fibrotic interstitial lung disease. This biomarker could aid in managing the condition and developing new therapies.
Area of Science:
- Pulmonology
- Genetics
- Biomarker Discovery
Background:
- Fibrotic interstitial lung diseases (ILDs) are a group of progressive lung diseases characterized by scarring of lung tissue.
- Predicting disease progression in ILDs is challenging, hindering timely treatment and therapeutic development.

